Halozyme Therapeutics held its 2026 Annual Meeting of Stockholders on May 5, where both Class I director nominees were elected, executive compensation was approved, and Ernst & Young LLP was ratified as auditors.
Key takeaways
Both Bernadette Connaughton (89.1M for, 4.8% against) and Matthew L. Posard (82.7M for, 11.4% against) elected as Class I directors for three-year terms.
Advisory vote on named executive officer compensation approved with 84.7M for versus 9.3M against.
Ratification of Ernst & Young LLP as auditors for FY 2026 passed overwhelmingly with 103.2M for and minimal opposition.
104.1M shares (88% of 118.5M outstanding) represented at the meeting.
All three proposals received majority approval from shares present.